Polymorphisms of DNA Repair Genes in Endometrial Cancer by unknown
RESEARCH
Polymorphisms of DNA Repair Genes in Endometrial Cancer
Anna Sobczuk & Tomasz Poplawski & Janusz Blasiak
Received: 22 March 2012 /Accepted: 12 April 2012 /Published online: 28 April 2012
# The Author(s) 2012. This article is published with open access at Springerlink.com
Abstract Endometrial cancer belongs to the commonest
malignancy in females. Its development may be associated
with the high exposure of endometrium to exo- and endog-
enous estrogens. Estrogens produce DNA bulky adducts and
oxidative base damages which are removed in nucleotide
excision repair (NER) and base excision repair (BER) path-
ways. The reaction of endometrial cells to DNA damage
may be crucial for their susceptibility to cancer transforma-
tion. This reaction is executed mainly by DNA repair, which
can be modulated by the variability in the genes encoding
DNA repair proteins. In this report we genotyped 4 poly-
morphisms of 3 DNA repair genes in 94 endometrial cancer
patients and 114 age-matched cancer-free women using
RFLP-PCR. The following polymorphisms were studied:
p.Arg194Trp, p.Arg399Gln of the XRCC1 gene,
p.Ser326Cys of the hOGG1 gene and p.Lys751Gln of the
ERCC2 gene. We found an association between the ERCC2
751Gln variant and endometrial cancer occurrence (OR
3.95; 95 % CI 1.88–8.31). Gene-gene interaction between
the ERCC2 751Gln and XRCC1 194Trp variants also in-
creased the risk of endometrial cancer (OR 4.41; 95 % CI
2.01–9.67). The risk in the carriers of the ERCC2 751Gln
variant was increased by a positive cancer history in first
degree relatives (OR 4.97; 95 % CI 1.98–12.48). The risk of
endometrial cancer was not alter by polymorphism
p.Ser326Cys of the hOGG1 gene. The 751 Lys/Gln poly-
morphism of the ERCC2 genemay be linkedwith endometrial
cancer occurrence and its effect can be potentiated by variants
of the XRCC1 gene or first degree relatives positive cancer
history.
Keywords XRCC1 . ERCC2 . hOGG1 . Endometrial
cancer . RFLP-PCR . BER . NER
Introduction
Endometrial carcinoma (EC) is the most common tumor of
the female genital tract in the Western world [1]. The great
majority of EC cases are type I (estrogen-related), frequently
showing microsatellite instability and mutations in the
PTEN, PIK3CA, K-Ras and β-catenin genes. These muta-
tions may reflect the genomic instability which is most
common symptom of the cancer cells [2, 3]. This instability
may be caused by a continuous exposure to genotoxic stress,
including that evoked by estrogens, which can induce bulky
DNA adducts and minor modifications to the DNA bases
[4]. These lesions are removed by nucleotide and base
excision repair (NER and BER), respectively. NER includes
recognition of DNA damage by the RAD23B-XPC com-
plex, followed by binding of the XPA/RPA dimer to the
lesion. XPA is an important factor for accurate positioning
of the ERCC1-ERCC4 (XPF) endonuclease. Two helicases
ERCC3 (XPB) and ERCC2 (XPD) are responsible for un-
winding the DNA helix, and the ERCC5 (XPG) and
ERCC1-ERCC4 nucleases excise a single stranded DNA
fragment containing the lesion. The remained gap is filled
by DNA polymerase δ/ε and DNA ligase I using the intact
strand as a template. The base excision repair (BER) path-
way corrects most base modifications caused by reactive
oxygen species (ROS). A damaged base is recognized by a
specific glycosylase, which cleaves the bond between the
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base and sugar, creating an abasic site, which is cleaved by
an endonuclease. Resulting gap is filled by polβ and the
remaining nick is sealed by DNA ligase LIG1 or LIG3
complexed with XRCC1.
Because NER and BER are involved in removing a
substantial number of DNA damages, which can contribute
to the genome instability, it is reasonable to check whether
variability in the genes coding for BER and NER products
may be associated with EC. In the present work we searched
for an association between EC and the variants of single
nucleotide polymorphisms (SNPs) of the BER/NER genes:
ERCC2, OGG1 and XRCC1. We studied 4 SNPs occurring
in 3 BER and NER genes: p.Arg194Trp, p.Arg399Gln of
the XRCC1 gene, p.Ser326Cys of the hOGG1 gene and
p.Lys751Gln of the ERCC2 gene (rs1799782, rs25487,
rs1052133 and rs13181 respectively). These polymorphisms
have been correlated with various tumors, including lung,
breast and skin cancers [5–13], but little is known about
their association with EC.
Materials and Methods
Patients
Blood was obtained from 94 women (median age 48 years
and median BMI 28) with EC treated in 2004–2006 at the
Polish Mother’s Memorial Hospital (Lodz, Poland). All
patients had histologically confirmed EC and agreed to
complete a risk factor questionnaire. The characteristics of
the subjects enrolled in this study are presented in Table 1.
Control samples consisted of DNA extracted from blood
cells from age-matched 114 cancer-free women. The study
was approved by the Local Ethic Committee and each
patient gave a written consent.
Genotype Determination
Genomic DNAwas prepared using GeneMatrix Blood DNA
purification Kit (EURx, Gdansk, Poland) according to the
manufacturer instruction. Genotypes were determined by
PCR-RFLP (polymerase chain reaction-restriction fragment
length polymorphism). Genome regions that include studied
polymorphisms were amplified by PCR using primers listed
in Table 2. The PCR reaction (total volume 25 μl) was
launched with a mixture containing 100 ng genomic DNA,
5 mM dNTPs, 5 pmol each primer and 1 U Taq DNA
polymerase (Biotools, Madrid, Spain) which was added into
PCR buffer containing 10 mM Tris–HCl, 1.5 μM MgCl2
and 50 mM KCl. PCR conditions were as follows: initial
denaturation step at 95 °C for 5 min, 30 cycles at 95 °C for
30 s and 30 s at the 62 °C annealing temperature, and at
72 °C for 30 s. The final extension step was performed at
Table 1 Characteristics of the study population






Elementary school 21 22
Secondary technical school 15 15
High school 38 50











Before 11 years 5 10
12–13 years 35 56
14–15 years 43 30
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72 °C for 5 min. The PCR was carried out in a MJ Research,
INC thermal cycler, model PTC-100 (Waltham, MA, USA).
Following PCR, 20 ml aliquots were removed and subjected
to restriction digestion with PvuII (for codon 194), BcnI (for
codon 399), SatI (for codon 326) or PstI (for codon 751).
All restriction enzymes were from Fermentas, Vilnius, Lith-
uania). The digested products were resolved on a 8 % ac-
rylamide gel and stained with 0.5 μg/ml ethidium bromide.
The cleavage of the XRCC1 fragment with PvuII produced
bands of 292/174/21, 313/292/174/21 and 313/174 bp
corresponding to the Arg/Arg, Arg/Trp and Trp/Trp geno-
types, respectively. The BcnI restrictase having acted on the
same fragment produced bands of 159/89, 248/159/89 and
248 bp corresponding to the 399 Arg/Arg, Arg/Gln and Gln/
Gln genotypes, respectively. The SatI restriction enzyme
yielded products of 200, 200/100/100 and 100 bp
corresponding to the Ser/Ser, Ser/Cys and Cys/Cys geno-
types of the OGG1 gene, respectively. The cleavage with
PstI produced fragments of 161, 161/120/41 and 120/41 bp
corresponding to the Lys/Lys, Lys/Gln and Gln/Gln geno-
types of the ERCC2 gene, respectively.
Data Analysis
Logistic regression analysis was used to compute odds ratio
(OR) and associated 95 % confidence interval (95 % CI)
relating each of the SNPs as well as combinations of SNPs
and another analysed factors presented in Table 1 to the risk
of EC. Only matching variables and factors that altered the
ORs by 10 % were included in the final multivariate models.
Analyses were performed using STATISTICA 10 package
(Statsoft, Tulsa, OK, USA).
Results
All distributions of genotypes did not differ significantly (p
<0.05) from those expected by the Hardy-Weinberg equi-
librium. An association (OR 3.95; 95 % CI 1.88–8.31) was
found between the Gln/Gln genotype of the p.Lys751Gln
polymorphism of ERCC2 gene and EC occurrence (Table 3).
There were no differences in the genotype distributions
between cancer patients and controls for the remaining poly-
morphisms (Tables 4, 5 and 6). We also analyzed combined
genotype of all polymorphism pairs. The Arg/Arg genotype
of the XRCC1 gene increased the risk of EC for the carriers
of the 751 Gln/Gln variant of the ERCC2 gene (Table 7). We
also found that the Cys/Cys and Arg/Arg genotypes of the
p.Ser326Cys polymorphism of the hOGG1 gene and the
Arg/Gln genotype of the XRCC1 gene decreased EC risk
(OR 0.50; 95 % CI 0.25–0.99) (Table 8). No difference
between genotype distributions was found for others com-
bined genotypes of the polymorphisms (data not shown).
Adjustment for first degree relatives cancer history in-
creased OR for the Gln/Gln genotype of the p.Lys751Gln
polymorphism of ERCC2 gene from OR 3.95; 95 % CI
1.88–8.31 to OR 4.97; 95 % CI 1.98–12.48. Other remain-
ing confounders, including postmenopausal hormone use
and body mass index, did not modify the observed estimates
of association.
Table 2 Primers used to analyze
p.Arg194Trp, p.Arg399Gln
polymorphisms of the XRCC1
gene, p.Ser326Cys polymor-








hOGG1 p.Ser326Cys forward 5’-GGAAGGTGCTTGGGGAAT-3’
reverse 5’-ACTGTCACTAGTCTCACCAG-3’
ERCC2 p.Lys751Gln forward 5’-CTGCTCAGCCTGGAGCAGC-3’
reverse 5’-TAGAATCAGAGAGAGGAGACGCTG-3’.
Table 3 The allele and genotype
frequency and odds ratio (OR)
of p.Lys751Gln polymorphism of
the ERCC2 gene in endometrial
cancer
Patients (n094) Controls (n0114)
Genotype or Allele Number Frequency Number Frequency OR (95 % CI)
Lys/Lys 30 0.32 38 0.33 0.93 (0.52–1.67)
Lys/Gln 36 0.38 64 0.56 0.48 (0.27–0.84)
Gln/Gln 28 0.30 12 0.11 3.95 (1.88–8,31)
Lys 96 0.52 140 0.61 0.65 (0.44–0.96)
Gln 92 0.48 88 0.39 1.52 (1.03–2.25)
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Discussion
In the present study we genotyped four common polymor-
phisms of the XRCC1, hOGG1 and ERCC2 DNA repair
genes and tested the association between the distributions
of their genotypes with EC. These polymorphisms have
been shown to have functional significance and may be in
part responsible, for the inter-individual difference in capac-
ity of DNA repair in the general population and for low
DNA repair efficacy in cancer patients [5–7, 14–17]. We
obtained a significantly higher OR than for other analyzed
polymorphisms, odds ratio for the Gln/Gln genotype of the
p.Lys751Gln polymorphism of the ERCC2 gene than for
genotypes of remaining polymorphisms. The protein
encoded by the ERCC2 gene is involved in transcription-
coupled NER and is an important member of the basal
transcription factor TFIIH. Exchange of 751 Lys for Gln in
the ERCC2 can lead to a conformational change in the
encoded protein at the domain of the interaction between
ERCC2 and its helicase activator, p44, inside the TFIIH
complex [18]. The Gln/Gln variant of the ERCC2 gene has
been associated with an increased risk of lung cancer [10,
11], and correlated with higher risk of skin, bladder and
breast cancer [12, 19, 20]. Surprisingly, this polymorphism
has been also linked with non-cancer diseases, such as
cataract [21]. To date, none studies have addressed the
association between alterations in this region of the ERCC2
gene and EC. Because a proper functioning of the ERCC2
gene is important for the genomic stability, its alternations
may be associated with a higher cancer susceptibility.
Type I EC are estrogen-related. The mechanisms by
which estrogens might cause the development of EC remain
unclear. Estrogens have the unique chemical structure that
distinguish them from other groups of hormones and their
metabolism in eukaryotic cells include formation of a vari-
ety of intermediate forms and production of ROS. Estrogens
undertake oxidative metabolism through hydroxylation
pathway, but the major intermediates are 2-OH and 4-OH
estrogens [22]. These chemicals are further oxidized to
semiquinones and quinones, which may form bulky DNA
adducts and may undergo redox cycling, producing ROS
that may cause oxidative stress, lipid peroxidation, and
DNA damage [23, 24]. Consequently, estrogen metabolism
in human cells may play a role in tumor initiation via direct
damage to the DNA by the formation of bulky DNA adducts
and/or by producing ROS that cause oxidative DNA damage.
These types of DNA damage are usually repaired by NER
and BER.
In our study we analyzed the association between three
polymorphisms of two genes of BER and EC. We did not
find any association when we analyzed each polymorphism
separately, but the analysis of combined genotypes showed
that they might significantly increase the risk of EC. The
results obtained suggest that polymorphisms of the XRCC1
and ERCC2 genes may modulate the risk and therefore play
a role in the etiology of EC. The XRCC1 protein has no
known catalytic activity but serves to orchestrate BER
through its role as a central scaffolding protein for DNA
ligase III, DNA polymerase β, and poly(ADP-ribose) poly-
merase (PARP) [25]. Arg/Trp variant of the p.Arg/Trp
Table 4 The allele and genotype
frequency and odds ratio (OR)
of the p.Ser326Cys polymor-
phism of the hOGG1 gene in en-
dometrial cancer
Patients (n094) Controls (n0114)
Genotype or Allele Number Frequency Number Frequency OR (95 % CI)
Ser/Ser 64 0.68 83 0.73 0.79 (0.43–1.44)
Ser/Cys 23 0.24 28 0.24 0.99 (0.52–1.87)
Cys/Cys 7 0.07 3 0.02 2.97 (0.74–11.84)
Ser 151 0.82 194 0.85 0.71 (0.42–1.19)
Cys 37 0.18 34 0.15 1.39 (0.83–2.33)
Table 5 The allele and geno-
type frequency and odds ratio
(OR) of the p.Arg399Gln poly-
morphism of the XRCC1 gene in
endometrial cancer
Patients (n094) Controls (n0114)
Genotype or Allele Number Frequency Number Frequency OR (95 % CI)
Arg/Arg 27 0.29 43 0.37 0.66 (0.37–1.19)
Arg/Gln 45 0.48 48 0.42 1.22 (0.72–2.18)
Gln/Gln 22 0.23 23 0.21 1.21 (0.62–2.34)
Arg 99 0.53 134 0.58 0.78 (0.52–1.15)
Gln 89 0.47 94 0.42 1.28 (0.86–1.89)
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polymorphism of the XRCC1 gene occurs in proliferating
cell nuclear antigen binding region, but few studies have
examined the influence of the Trp/Trp genotype of this
polymorphism on the function of the XRCC1 protein [26,
27]. This variant has been associated with a lower bleomy-
cin and benzo(a)pyrene diol-epoxide sensitivity in vitro [16,
28]. These data suggest a protective role of the Trp/Trp
genotype of the p.Arg/Trp polymorphism of the XRCC1
gene against the development of cancer and this function
can be underlined by increasing the activity of BER. This is
in agreement with our result suggesting a potential role of
the Arg/Arg genotype of the p.Arg/Trp polymorphism of the
XRCC1 gene with reduced BER capacity as compared with
Trp/Trp genotype in EC.
We have also found that cancer history in first degree
relatives increased endometrial cancer risk in the Gln/Gln
variant of the p.Lys751Gln polymorphism of the ERCC2
gene. This result may suggest hereditary background of EC
cancer and/or major contribution of the p.Lys751Gln poly-
morphism of the ERCC2 gene in cancer development but
more studies performed on larger population is needed to
draw a final conclusion.
Table 6 The allele and genotype
frequency and odds ratio (OR)
of the p.Arg194Trp polymor-
phism of the XRCC1 gene in en-
dometrial cancer
Patients (n094) Controls (n0114)
Genotype or Allele Number Frequency Number Frequency OR (95 % CI)
Arg/Arg 89 0.95 103 0.90 1.90 (0.64–5.67)
Arg/Trp 5 0.05 11 0.10 0.53 (0.17–1.57)
Trp/Trp 0 – 0 – –
Arg 183 0.97 217 0.95 1.85 (0.63–5.43)
Trp 5 0.03 11 0.05 0.50 (0.18–1.57)
Table 7 The distribution of
combined genotypes of the of
the p.Arg194Trp polymorphism
of the XRCC1 gene and
p.Lys571Gln polymorphism of
the ERCC2 gene in endometrial
cancer
Patients (n094) Controls (n0114)
Genotype or Allele Number Frequency Number Frequency OR (95 % CI)
Arg/Arg – Lys/Lys 28 0.30 36 0.31 0.92 (0.51–1.66)
Arg/Arg – Lys/Gln 33 0.35 57 0.50 0.54 (0.31–0.95)
Arg/Arg – Gln/Gln 28 0.30 10 0.09 4.41 (2.01–9.67)
Arg/Trp – Lys/Lys 2 0.02 2 0.02 1.21 (0.16–8.81)
Arg/Trp – Lys/Gln 3 0.03 7 0.06 0.49 (0.12–1.96)
Arg/Trp – Gln/Gln 0 – 2 0.02 –
Trp/Trp – Lys/Lys 0 – 0 – –
Trp/Trp – Lys/Gln 0 – 0 – –
Trp/Trp – Gln/Gln 0 – 0 – –
Table 8 The distribution of
combined genotypes of the
p.Ser326Cys polymorphism of
the hOGG1 gene and
p.Arg399Gln polymorphism of
the XRCC1 gene in endometrial
cancer
Patients (n094) Controls (n0114)
Genotype or Allele Number Frequency Number Frequency OR (95 % CI)
Ser/Ser – Arg/Arg 16 0.17 33 0.29 0.50 (0.25–0.99)
Ser/Ser – Arg/Gln 30 0.32 34 0.30 1.10 (0.61–1.99)
Ser/Ser – Gln/Gln 18 0.19 16 0.14 1.45 (0.69–3.01)
Ser/Cys – Arg/Arg 9 0.10 9 0.08 1.23 (0.47–3.25)
Ser/Cys – Arg/Gln 12 0.13 12 0.10 1.24 (0.53–2.91)
Ser/Cys – Gln/Gln 2 0.02 7 0.06 0.33 (0.06–1.63)
Cys/Cys – Arg/Arg 2 0.02 1 0.01 2.45 (0.21–27.52)
Cys/Cys – Arg/Gln 3 0.03 2 0.02 1.85 (0.32–11.28)
Cys/Cys – Gln/Gln 2 0.02 0 – –
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In summary, our results suggest that the 751 Gln/Gln
variant of the p.Lys751Gln polymorphism of the ERCC2
gene can be associated with the occurrence of EC. We have
also showed that the Arg/Arg variant of the p. Arg194Trp
polymorphism of the XRCC1 gene increased the risk of EC
in individuals with the Gln/Gln variant of the ERCC2 gene.
The data obtained suggest also that positive cancer history
in first degree relatives in connection with Gln/Gln variant
of the p.Lys751Gln polymorphism of the ERCC2 gene may
be associated with EC.
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